Conhecimento

HIPRA R&D Projects

Humoral immune response against XBB.1.5 and BQ.1.1 SARS-CoV-2 variants of a fourth dose of PHH-1V vaccine in adult subjects

HIPRA R&D Projects

Reactogenicity of third and fourth booster doses of HIPRA PHH-1V, a bivalent recombinant protein vaccine against SARS-CoV-2

Laboratory technician of R&D_HIPRA

Humoral immune response against SARS-CoV-2 variants of PHH-1V booster vaccine in subjects previously vaccinated with a mRNA vaccine

One-year humoral response of PHH-1V booster vaccine in subjects previously vaccinated against COVID-19 with a mRNA vaccine. Results of a pivotal randomised controlled trial

One-year humoral response of PHH-1V booster vaccine in subjects previously vaccinated against COVID-19 with a mRNA vaccine

Alex Soriano

Dr. Àlex Soriano (Hospital Clínic de Barcelona): "Public-private collaboration is essential to achieve significant scientific advances"

HIPRA laboratory R&D

Update on BIMERVAX® immunogenicity amplitude. Insights on humoral response against XBB.1.5 from an extension study

HIPRA laboratory R&D

Alicante-Winter Immunology Symposium in Health (A-Wish) and the Boulle-SEI awards

The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19

The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19

How do COVID-19 vaccines work?

How do COVID-19 vaccines work?